Community curated by people like you

Hypertrophic cardiomyopathy stories

Aug 28, 2026

Cytokinetics reports positive late-stage data for heart drug aficamten

Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.

Aug 28, 2026·2 sources

00

Top claims

▪Barclays analysts expect that holding the non-obstructive hypertrophic cardiomyopathy market will trigger a halo effect that boosts Cytokinetics' existing sales for obstructive hypertrophic cardiomyopathy
▪Bristol Myers plans to start a late-stage study of its rival drug, Camzyos, in patients with non-obstructive hypertrophic cardiomyopathy later in 2026
▪Cytokinetics' drug aficamten is already approved under the brand name Myqorzo for obstructive hypertrophic cardiomyopathy, which causes thickened heart muscles to block blood flow

Topics

Genetic disorders Pharmaceutical Industry

Featured Stories

CIA Director John Ratcliffe arrives in Moscow aboard US military plane for meetings

Aug 25, 2026·8 sources